Meta-analysis finds no significantly increased risk, except for increased ventricular arrhythmias at higher doses.
Takeaway
- Glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy was not significantly associated overall with incident arrhythmias in people with type 2 diabetes (T2D) or obesity.
- Higher ventricular arrhythmia risk was seen with higher GLP-1RA doses.
Why this...
